Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFN-gamma 1-b effects on innate immune cells
NCT02609932Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- Jul 2016
- Primary completion
- Aug 2018
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of interferon gamma-1b in chronic granulomatous disease (CGD) (2 arms), sponsored by University of Colorado Denver. Primary endpoints: Change in Neutrophil Nox2 activity at 96 hours, Change in Plasma IL-10 and Neuropterin concentration at 96 hours and 2 more. Started Jul 2016; status: completed.
02
Drugs
interferon gamma-1b
03
Conditions
chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on NCT02609932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02609932.